Mark Goldberg, MD, is a medical oncologist and hematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society (ACS) and ACS Cancer Action Network (CAN) volunteer.  Dr. Goldberg currently serves on the boards of directors of ImmunoGen, GlycoMimetics, Walden Biosciences, Avacta Group plc, and Blueprint Medicines.  Dr. Goldberg previously served on the executive management team of Synageva Biopharma from 2011-2014 and before that served in various management capacities of increasing responsibility at Genzyme Corporation from 1996-2011, most recently as senior vice president of clinical development.  Dr. Goldberg is the past-chair of the Eastern New England Area Board and was a member of the former New England Division Board. He has served on the American Cancer Society Board of Directors since 2019. He received his bachelor’s degree from Harvard College and his medical degree from Harvard Medical School.